Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Rajasthan cohort of the A 1 chieve study
Autor: | Anand Meenawat, Shashi Panicker, Rajeev Patni, Akhil Joshi, Dinesh C Sharma |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2013 |
Předmět: |
medicine.medical_specialty
endocrine system diseases type 2 diabetes mellitus Endocrinology Diabetes and Metabolism A1chieve study insulin analogues Type 2 diabetes lcsh:Diseases of the endocrine glands. Clinical endocrinology Insulin aspart Endocrinology A 1 chieve study Internal medicine medicine lcsh:RC799-869 Insulin detemir lcsh:RC648-665 business.industry Type 2 Diabetes Mellitus nutritional and metabolic diseases medicine.disease Biphasic insulin aspart Rajasthan Cohort Original Article lcsh:Diseases of the digestive system. Gastroenterology business hormones hormone substitutes and hormone antagonists medicine.drug |
Zdroj: | Indian Journal of Endocrinology and Metabolism, Vol 17, Iss 8, Pp 526-529 (2013) Indian Journal of Endocrinology and Metabolism |
ISSN: | 2230-9500 2230-8210 |
Popis: | Background: The A 1 chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care across four continents. Materials and Methods: Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from Rajasthan, India. Results: A total of 477 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Patients had started on or were switched to biphasic insulin aspart (n = 340), insulin detemir (n = 90), insulin aspart (n = 37), basal insulin plus insulin aspart (n = 7) and other insulin combinations (n = 2). At baseline glycaemic control was poor for both insulin naïve (mean HbA 1 c: 8.3%) and insulin user (mean HbA 1 c: 8.4%) groups. After 24 weeks of treatment, both the groups showed improvement in HbA 1 c (insulin naïve: −0.9%, insulin users: −1.2%). Major hypoglycaemic events decreased from 0.5 events/patient-year to 0.0 events/patient-year in insulin naïve group while no change from baseline (1.3 events/patients-year) was observed for insulin users. SADRs were not reported in any of the study patients. Conclusion: Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia. |
Databáze: | OpenAIRE |
Externí odkaz: |
načítá se...